The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

As New Zealand eyes a free trade agreement with India, experts say the next frontier could be pharmaceutical imports - ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy.